2023
HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing
Lyons D, Kumar P, Roan N, Defechereux P, Feschotte C, Lange U, Murthy N, Sameshima P, Verdin E, Ake J, Parsons M, Nath A, Gianella S, Smith D, Kallas E, Villa T, Strange R, Mwesigwa B, O’Brien R, Nixon D, Ndhlovu L, Valente S, Ott M. HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing. Viruses 2023, 15: 2171. PMID: 38005849, PMCID: PMC10674359, DOI: 10.3390/v15112171.Peer-Reviewed Original ResearchChanges in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study
Bergerot C, Philip E, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin Z, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clinical Genitourinary Cancer 2023, 21: 626-630.e3. PMID: 37391301, PMCID: PMC11225089, DOI: 10.1016/j.clgc.2023.05.018.Peer-Reviewed Original ResearchConceptsPerception of cureExpectation of cureGenitourinary cancersImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsProportion of patientsSevere side effectsLongitudinal studyChi-square testICI therapyCheckpoint inhibitorsInhibitor therapyECOG scoreGeneral linear modelingPatients' perceptionsMetastatic cancerPatientsSide effectsDecreased anxietyTherapyCancerCureLower ratesAnxiety Scale
2022
Determining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set
Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S, Tsertsvadze T, Kamkamidze G, Alkhazashvili M, Morgan T, Belperio P, Backus L, Doss W, Esmat G, Hassany M, Elsharkawy A, Elakel W, Mehrez M, Foster GR, Kinge C, Chew KW, Chasela CS, Sanne IM, Thanung YM, Loarec A, Aslam K, Balkan S, Easterbrook PJ, Linas BP. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set. Journal Of Viral Hepatitis 2022, 29: 474-486. PMID: 35278339, PMCID: PMC9248016, DOI: 10.1111/jvh.13672.Peer-Reviewed Original ResearchConceptsDetectable viraemiaDetectable HCV RNALow-level viraemiaVirological treatment failureHCV viral loadTest of cureHepatitis C virusViral load assaysHCV viraemiaHCV RNATreatment failureViral loadC virusClinical trialsMinimal fibrosisSVR12ViraemiaGlobal eliminationLogistic regressionDiagnostic performanceLevel of detectionObservational databaseIULaboratory-based assaysCure
2019
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings
Farrell A, Panepinto J, Desai A, Kassim A, Lebensburger J, Walters M, Bauer D, Blaylark R, DiMichele D, Gladwin M, Green N, Hassell K, Kato G, Klings E, Kohn D, Krishnamurti L, Little J, Makani J, Malik P, McGann P, Minniti C, Morris C, Odame I, Oneal P, Setse R, Sharma P, Shenoy S. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances 2019, 3: 4002-4020. PMID: 31809537, PMCID: PMC6963248, DOI: 10.1182/bloodadvances.2019000883.Peer-Reviewed Original ResearchConceptsLow-resource settingsEnd pointClinical trial end pointsTrial end pointsPatient-reported outcomesSickle cell disease clinical trialsPanel of cliniciansSickle cell diseaseMeasurement of cureClinical trialsNovel therapiesCell diseaseConsensus recommendationsGlobal burdenUS FoodBiomarker panelDrug AdministrationAvailable evidenceAmerican SocietyCureRelevant findingsLiterature reviewPainPatientsTherapyTime-to-cure and cure proportion in solid cancers in France. A population based study
Romain G, Boussari O, Bossard N, Remontet L, Bouvier A, Mounier M, Iwaz J, Colonna M, Jooste V, Registries F. Time-to-cure and cure proportion in solid cancers in France. A population based study. Cancer Epidemiology 2019, 60: 93-101. PMID: 30933890, DOI: 10.1016/j.canep.2019.02.006.Peer-Reviewed Original ResearchConceptsTestis cancerCancer sitesThyroid cancerCure proportionFrench cancer registriesMost cancer sitesLarge national databaseHealthcare policy makersGynaecologic cancerYounger patientsCancer RegistryColorectal cancerSurvival cure modelUrinary tractCancer careDigestive cancersSolid cancersSkin melanomaSolid tumorsSmall intestineCancerPatientsNational databaseBreastCure
2018
A new approach to estimate time-to-cure from cancer registries data
Boussari O, Romain G, Remontet L, Bossard N, Mounier M, Bouvier A, Binquet C, Colonna M, Jooste V. A new approach to estimate time-to-cure from cancer registries data. Cancer Epidemiology 2018, 53: 72-80. PMID: 29414635, DOI: 10.1016/j.canep.2018.01.013.Peer-Reviewed Original ResearchConceptsPopulation-based cancer dataFlexible parametric cure modelsThyroid cancer patientsCancer registry dataParametric cure modelsCancer RegistryColorectal cancerCancer patientsPancreatic cancerCancer sitesBreast cancerRegistry dataCure modelAge groupsCancerCureDiagnosisSurvival frameworkCure fractionPatientsHealth insurance premiumsFrench networkSurvival time distributionYears
2017
Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
Berger BA, Cossio A, Saravia NG, del Mar Castro M, Prada S, Bartlett AH, Pho MT. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis. PLOS Neglected Tropical Diseases 2017, 11: e0005459. PMID: 28384261, PMCID: PMC5404883, DOI: 10.1371/journal.pntd.0005459.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAntiprotozoal AgentsCaregiversChildChild, PreschoolCost-Benefit AnalysisDirectly Observed TherapyDrug CostsFemaleHumansInjections, IntramuscularLeishmaniaLeishmaniasis, CutaneousMaleMeglumineMeglumine AntimoniateMonte Carlo MethodOrganometallic CompoundsPhosphorylcholineSensitivity and SpecificityTreatment OutcomeUnited StatesConceptsPediatric cutaneous leishmaniasisMeglumine antimoniateCutaneous leishmaniasisGovernment payer perspectivePayer perspectivePatient's perspectiveMean differenceSocietal perspectiveCost-effectiveness analysisSurvey of providersOral miltefosineAdverse eventsObserved therapyPrimary outcomeHealthcare utilizationClinical trialsMean costTreatment efficacyDrug effectivenessMiltefosineHome caregiversSocietal costsLeishmaniasisCureTreatmentSetting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa
Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, Walensky RP. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. Open Forum Infectious Diseases 2017, 4: ofx081. PMID: 28680903, PMCID: PMC5490502, DOI: 10.1093/ofid/ofx081.Peer-Reviewed Original ResearchHIV cure strategiesCure strategiesHuman immunodeficiency virus (HIV) eradicationLifetime antiretroviral therapySustained viral eradicationElimination of HIVStandard of careLifetime costsAntiretroviral therapyViral eradicationHIV cureFatal toxicitySingle interventionVirus eradicationLife expectancyCureLower lifetime costsSingle caseSurvival
2013
Cure Predictability During Parathyroidectomy
Udelsman R, Donovan P, Shaw C. Cure Predictability During Parathyroidectomy. World Journal Of Surgery 2013, 38: 525-533. PMID: 24240672, DOI: 10.1007/s00268-013-2327-8.Peer-Reviewed Original ResearchConceptsPostoperative parathyroid hormoneResidual diseaseCure rateTermination of surgeryConsecutive unselected patientsMean cure rateLogistic stepwise regressionCervical explorationPTH curveCurative resectionPrimary hyperparathyroidismPTH valuesUnselected patientsParathyroid hormoneSA patientsHyperfunctioning tissueOperative casesPatientsSubsequent cohortsLog oddsResectionCureAdditional explorationDiseaseCalcium data
2007
Hope and Prognostic Disclosure
Mack JW, Wolfe J, Cook EF, Grier HE, Cleary PD, Weeks JC. Hope and Prognostic Disclosure. Journal Of Clinical Oncology 2007, 25: 5636-5642. PMID: 18065734, DOI: 10.1200/jco.2007.12.6110.Peer-Reviewed Original ResearchConceptsPrognostic disclosurePrognostic informationPhysician communicationDana-Farber Cancer InstituteDisclosure of prognosisHalf of parentsChildren's HospitalParents of childrenChild's physicianMultivariable modelMAIN OUTCOMEParental recallCancer InstituteChild's oncologistChildren's CancerPatients' hopePhysiciansCancerEmotional distressPrognosisOncologistsHospitalChildren's likelihoodFirst yearCureHope and prognostic disclosure
Mack J, Cook E, Wolfe J, Grier H, Cleary P, Weeks J. Hope and prognostic disclosure. Journal Of Clinical Oncology 2007, 25: 6510-6510. DOI: 10.1200/jco.2007.25.18_suppl.6510.Peer-Reviewed Original ResearchPrognostic informationPrognostic disclosureParents of childrenPhysician communicationDana-Farber Cancer InstituteDisclosure of prognosisAdditional prognostic informationChildren's likelihoodChildren's HospitalChild's physicianMultivariable modelCancer InstituteChild's prognosisParent recallPrognosisPhysiciansCancer treatmentSignificant financial relationshipParental reportsFive-item indexHospitalCancerFirst yearCureChildrenUnderstanding of Prognosis Among Parents of Children With Cancer: Parental Optimism and the Parent-Physician Interaction
Mack JW, Cook EF, Wolfe J, Grier HE, Cleary PD, Weeks JC. Understanding of Prognosis Among Parents of Children With Cancer: Parental Optimism and the Parent-Physician Interaction. Journal Of Clinical Oncology 2007, 25: 1357-1362. PMID: 17416854, DOI: 10.1200/jco.2006.08.3170.Peer-Reviewed Original ResearchConceptsChance of cureLikelihood of cureParents of childrenFunctional outcomeDana-Farber Cancer InstituteKnowledge of prognosisUnderstanding of prognosisCross-sectional surveyChildren's HospitalMajority of parentsChild's physicianPhysicians' beliefsCancer InstitutePhysician expectationsPrognosisCancerPhysiciansCancer treatmentCureCancer therapyOutcomesPatientsParents' preferencesPlace parentsUnrealistic expectations
2006
Understanding of prognosis among parents of children with cancer: Parental optimism and the role of the parent-physician interaction
Mack J, Cook E, Wolfe J, Grier H, Cleary P, Weeks J. Understanding of prognosis among parents of children with cancer: Parental optimism and the role of the parent-physician interaction. Journal Of Clinical Oncology 2006, 24: 6033-6033. DOI: 10.1200/jco.2006.24.18_suppl.6033.Peer-Reviewed Original ResearchParents of childrenChild's physicianPhysicians' perceptionsDana-Farber Cancer InstituteMain outcome measuresUnderstanding of prognosisCross-sectional surveyChildren's HospitalMajority of parentsPhysician ratingsOutcome measuresCancer InstituteChild's prognosisPrognosisCancerPhysiciansPrognostic estimatesSignificant financial relationshipParents' confidenceCureMost parentsHospitalChildren's likelihoodChildrenChildren's chances
2005
Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran
Mirsaeidi SM, Tabarsi P, Khoshnood K, Pooramiri MV, Rowhani-Rahbar A, Mansoori SD, Masjedi H, Zahirifard S, Mohammadi F, Farnia P, Masjedi MR, Velayati AA. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. International Journal Of Infectious Diseases 2005, 9: 317-322. PMID: 16183321, DOI: 10.1016/j.ijid.2004.09.012.Peer-Reviewed Original ResearchConceptsMultiple drug-resistant tuberculosisMore second-line drugsDrug-resistant tuberculosis treatmentMDR-TB patientsMDR-TB treatmentMasih Daneshvari HospitalDrug-resistant tuberculosisSecond-line drugsAppropriate treatment regimensProbable cureDrug regimenTreatment regimenComplete followTreatment regimensTuberculosis treatmentPatientsAverage durationRegimenTreatmentDrugsCureRegimensAmikacinHospitalFollow
2003
Opportunistic screening for Chlamydia at a community based contraceptive service for young people
Moens V, Baruch G, Fearon P. Opportunistic screening for Chlamydia at a community based contraceptive service for young people. The BMJ 2003, 326: 1252. PMID: 12791743, PMCID: PMC1126124, DOI: 10.1136/bmj.326.7401.1252.Peer-Reviewed Original ResearchConceptsTest of cureContraceptive servicesHigh-risk womenPercentage of clientsPrevalence of infectionChlamydia screeningOpportunistic screeningChlamydia infectionRisk womenSectional studyHigh prevalenceAge groupsYoung womenInfectionMedical staffInfected casesYoung peopleReception staffEquivocal resultsPsychotherapy servicesChlamydiaPrevalenceWomenCureTreatment
2001
Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy
Nejat R, Purohit R, Goluboff E, Petrylak D, Rubin M, Benson M. Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy. Urologic Oncology Seminars And Original Investigations 2001, 6: 53-55. PMID: 11166621, DOI: 10.1016/s1078-1439(00)00098-3.Peer-Reviewed Original ResearchSmall cell carcinomaUrinary bladderCell carcinomaUndifferentiated small cell carcinomaM-VAC chemotherapyRecurrence 3 yearsRadical surgeryPathologic evidenceRadical cystoprostatectomyCisplatin chemotherapyAggressive malignancyApparent cureChemotherapyBladderCarcinomaCureCystectomyCystoprostatectomyPatientsSurgeryMalignancyRadiotherapyTumorsAdriamycin
1985
Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up.
JOHNSON B, IHDE D, BUNN P, BECKER B, WALSH T, WEINSTEIN Z, MATTHEWS M, WHANG-PENG J, MAKUCH R, JOHNSTON-EARLY A, LICHTER A, CARNEY D, COHEN M, GLATSTEIN E, MINNA J. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Annals Of Internal Medicine 1985, 103: 430-8. PMID: 2992337, DOI: 10.7326/0003-4819-103-3-430.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrainCarcinoma, Small CellCombined Modality TherapyFemaleFollow-Up StudiesHematologic DiseasesHumansLung NeoplasmsMaleMemory DisordersMiddle AgedNeoplasm Recurrence, LocalNervous System DiseasesRadiotherapyRespiratory Function TestsConceptsSmall cell lung cancerLung cancerCombination chemotherapyEvidence of cancerCancer-free survivalCell lung cancerCranial irradiationAggressive therapyLate toxicityUnrelated causesLate relapseTherapeutic trialsCancer 5PatientsPotential cureThirty-monthCancerChemotherapyRelapseCureChronic toxicityMonthsSurvivalEleven yearsToxicity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply